1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
69A6F9021532823BE65257BAC003EC66E
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/building-medical-affairs-capabilities-in-India-report?opendocument
18
19opendocument
2018.208.211.150
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services ╗

Building Best-in-Class Medical Affairs Capabilities In India – A Case Study For High-Growth Emerging Markets

ID: POP-249


Features:

9 Info Graphics

21 Data Graphics

150+ Metrics

14 Narratives


Pages: 61


Published: 2013


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Medical Affairs function at bio-pharmaceutical companies plays a vital role in bridging the gap between commercial and R&D operations. Evidently, across the global healthcare landscape, the Medical Affairs function is essential to meeting current challenges in clinical development, market education, and regulatory compliance.

Iná India, the
Medical Affairs function is still developing, following a similar path to maturity as that traveled by MA groups in Mature Markets. Medical Affairs groups in India need to establish a clear value proposition in order to evolve beyond their traditional roles.

Best Practices, LLC's recent case study illustrates how mature and Indian biopharmaceutical companies include
Abbott, Alkem Laboratories, AstraZeneca, Biocon, MSD Pharma, Ranbaxy, Sanofi & Astellas Pharma are structuring and managing their Medical Affairs organizations today. The study also examines recent trends in budget and staffing resources, key challenges and top success factors for the function particularly for Indian organizations.

Industries Profiled:
Pharmaceutical; Biotech; Health Care; Biopharmaceutical; Diagnostic; Laboratories; Chemical; Technology; Medical Device; Manufacturing; Financial Services; Consumer Products


Companies Profiled:
Pfizer; LifeCell; Biocon; Biogen Idec; Alkem; AstraZeneca; Ipsen; Esteve; Guerbet; Endo Pharmaceuticals; Allergan; BD; Methapharm; GlaxoSmithKline ; Gilead Sciences; Ethicon; Johnson & Johnson; Mylan; Forest Laboratories; MedImmune; Upsher-Smith; Grunenthal; Phillips; Sandoz; Baxter International; ONYX; Xanodyne Pharmaceuticals; ViroPharma; Ranbaxy; Bristol-Myers Squibb; Novartis; Medtronic; Astellas; GE Healthcare; Eisai; Roche; Teva Pharmaceutical Industries Ltd; MSD; Bayer; Boehringer Ingelheim; Shire; Novo Nordisk; Sanofi Pasteur; Genentech; Cubist Pharmaceuticals; UCB Pharma; Sunovion; Valeant


Study Snapshot

This study engaged executives from 50 leading healthcare companies. Segmentation analysis was key to examining trends and effective practices. Within the Mature Markets Segment, 41 participants make up the Pharmaceutical Segment, while the Medical Device Segment consists of 12 participants. The India Segment consists of 8 companies working actively in the India market.

Key topics include:

  • Medical Affairs: Scope & Structure
  • Medical Affairs: Leadership & Oversight
  • Medical Affairs: Regulatory Landscape & Challenges
  • Medical Affairs: Spend Allocations & Investment Benchmarks
  • Medical Affairs: Staffing Benchmarks
  • Medical Affairs: Functional Responsibility & Service Benchmarks
  • Medical Affairs: Budget Trends & Success Factor Benchmarks
  • Participant Demographic Data

Sample Key Findings

Global Scope of Medical Affairs: All Mature Market participants have a group dedicated to Medical Affairs. Among companies in India, 89% have a fully dedicated Medical Affairs group based in India, illustrating how Medical Affairs has grown into a global function with emerging market MA groups now a normal practice.
  • Mature Market Medical Affairs Reporting into R&D, Becoming Own Entity; India Medical Affairs Reporting to Commercial: Four out of 10 mature market groups in the benchmark class report to R&D. As a function, Medical Affairs tends to more aligned with R&D, reflecting a common drive to differentiate itself from the commercial side of the organization. However, half of India segment participants report into Commercial/Marketing highlighting the fact that MA in India is still in formative stages.
Table of Contents

Executive Summary
    • Research Overview
    • Participating Companies
    • Key Recommendations
    • Maturity of Medical Affairs
    • Key Findings & Insights
  • Scope & Structure
  • Leadership & Oversight
  • Regulatory Landscape & Challenges
  • Spend Allocation
  • Staffing
  • Functional Responsibility
  • Budget Trends & Success Factors
  • Participant Demographics

Sample List of Charts & Exhibits

Medical Affairs group dedication
  • Departmental reporting relationships
  • Job level or Medical Affairs head
  • Geographic span of organization
  • Percentage of spending per Medical Affairs function
  • Directional trends in Medical Affairs funding levels
  • Directional trends in staffing levels
  • Reasons cited for budget/staff increases
  • Reasons cited for budget/staff decreases
  • Relative importance of seven different Medical Affairs functions
  • Reasons cited for increased importance
  • Reasons cited for decreased importance
  • Percentage of budget allocated for outsourcing
  • Percent of companies impacted by FDA Revitalization Act
  • Top three success factors for developing and maintaining effective Medical Affairs group
  • Top three challenges for developing and maintaining effective Medical Affairs group